China SXT's new lyophilisation facility secures pharmaceutical manufacturing permit

The move, coupled with the plants's passing of a pharmaceutical GMP compliance inspection, will enable company to accelerate the R&D of its novel Advanced TCMPs

The same facility has also passed a pharmaceutical GMP compliance inspection.

According to China SXT, this status makes it the first manufacturer of Directly-Oral traditional Chinese medicine pieces (TCMP) — a type of traditional Chinese medicine that has been processed to be ready for use — in China to have gained this status.

The lyophilisation -- or freeze drying -- process enables China SXT Pharmaceuticals to manufacture its Directly-Oral TCMPs and After-Soaking-Oral TCMPs, as it keeps their temperature-sensitive components in a frozen and dry condition. This in turn allows them to remain unchanged, thus delivering better quality products.

Mr Feng Zhou, CEO of China SXT, said the permit will further accelerate the company's R&D of new Advanced TCMPs.